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Overgrowth disorders are a heterogeneous group of conditions characterised by 
increased growth parameters and variable other clinical features, such as intellectual 
disability and facial dysmorphism1. To identify novel causes of human overgrowth we 
performed exome sequencing in 10 proband-parent trios and detected two de novo 
DNMT3A mutations. We identified 11 additional de novo mutations through DNMT3A 
sequencing of a further 142 individuals with overgrowth. The mutations were all 
located in functional DNMT3A domains and protein modelling suggests they interfere 
with domain-domain interactions and histone binding. No similar mutations were 
present in 1000 UK population controls (13/152 vs 0/1000; P<0.0001). Mutation carriers 
had a distinctive facial appearance, intellectual disability and increased height. 
DNMT3A encodes a key methyltransferase essential for establishing the methylation 
imprint in embryogenesis and is commonly somatically mutated in acute myeloid 
leukaemia2-4. Thus DNMT3A joins an emerging group of epigenetic DNA and histone 
modifying genes associated with both developmental growth disorders and 
haematological malignancies5. 
The control of human growth is highly complex and influenced by common and rare genetic 
variation6. The study of human overgrowth syndromes, which are characterised by increased 
prenatal and postnatal growth relative to age-related peers, has led to significant insights 
into fundamental biological processes involved in growth control1. As many growth disorders 
present as non-familial cases with a distinctive phenotype we hypothesised that de novo 
gene mutations may underlie some cases. To investigate this we are conducting trio-based 
exome sequencing in individuals with overgrowth and their parents using the Illumina 
TruSeq exome enrichment array. We are performing sequencing with an Illumina HiSeq 
2000, aligning the data with Stampy, performing variant calling with Platypus, variant 
annotation with SAVANT and identifying potential de novo variants using a custom R script.  
Review of the first 10 trios revealed two with apparent de novo mutations in DNMT3A (DNA 
cytosine 5 methyltransferase 3A), which was of immediate interest because of the functional 
relationship of this gene with EZH2, a known overgrowth predisposition gene we previously 
identified as the cause of Weaver syndrome7,8. By Sanger sequencing we confirmed the 
mutations, an inframe deletion p.Trp297del in COG0274 and a nonsynonymous mutation, 
p.Leu648Pro in COG0553, were present in the proband but not in the parents (Table 1, 
Supplementary Figure 1). 
To further evaluate the role of DNMT3A, we sequenced the full coding sequence and intron-
exon boundaries of the gene by Sanger sequencing in a further 142 individuals with 
overgrowth in whom mutations in NSD1, EZH2 and PTEN and dysregulation of the 11p15 
growth regulatory region had been excluded, and for whom parental DNA was also available 
(Supplementary Table 1). We identified an additional 11 de novo DNMT3A mutations. Thus 
in total, we found 13 different de novo DNMT3A mutations in 152 individuals with overgrowth 
phenotypes: 10 nonsynonymous mutations, two small frameshifting insertions and one 
inframe deletion (Figure 1, Table 1, Supplementary Figure 1). These data establish DNMT3A 
mutations as a cause of a novel human disorder, which we have termed ‘DNMT3A 
overgrowth syndrome’.  
A consistent phenotype, characterised by a distinctive facial appearance, tall stature and 
intellectual disability, was evident amongst the thirteen individuals with de novo DNMT3A 
mutations (Figure 2, Table 1). The facial gestalt was characterised by a round face, heavy, 
horizontal eyebrows and narrow palpebral fissures (Figure 2). Height was increased in all 
individuals ranging from 1.8 to 4.2 (mean 3.0) standard deviations above the mean. Head 
circumference was also increased ranging from 1.2 to 5.1 (mean 2.5) standard deviations 
above the mean. Intellectual disability, which was described as moderate in 11 individuals 
and mild in the remaining two, is also a key feature of the condition. Other, less frequent 
clinical features were variably present (Table 1). More detailed phenotyping in larger series 
are required to evaluate if these are real associations of DNMT3A mutations and to better 
define the clinical spectrum of this new overgrowth syndrome.   
In eukaryotic DNA, methylation preferentially occurs at cytosine bases which are converted 
to 5-methylcytosine by four DNA methyltransferase enzymes: DNMT3A, DNMT3B, DNMT1 
and DNMT3L2.  DNMT3A and DNMT3B are essential for the establishment of new 
methylation marks following erasure of parental methylation patterns during early embryonic 
development and for the establishment of sex-dependent methylation marks of imprinted 
genes during gametogenesis9-11. By contrast, DNMT1 is essential for the maintenance and 
conservation of DNA methylation marks after DNA replication10. DNMT3L does not possess 
inherent enzymatic activity but appears to physically interact with DNMT3A and stimulate its 
enzymatic activity12-14.   
 
DNMT3A contains three functional domains: a proline-tryptophan-tryptophan-proline 
(PWWP) domain; an ATRX-DNMT3A-DNMT3L-type zinc finger (ADD) domain and a C 
terminal DNA methyltransferase domain (Figure 1). It is noteworthy that all the mutations we 
identified were located in these domains. None were present in 1000 exomes from a UK 
population control series that were sequenced and analysed in a similar fashion. Moreover, 
no other frameshifting or nonsynonymous mutations in domains were present in the control 
exomes; four nonsynonymous variants were detected, but all were outside the functional 
domains (Figure 1). These data provide further evidence that the DNMT3A mutations in 
cases are pathogenic (13/152 vs 0/1000, P<0.0001). 
DNMT3A is one of the most frequently mutated genes in acute myeloid leukemia (AML)3,4,15. 
Somatic DNMT3A mutations are detected in approximately one third of cytogenetically 
normal AML and have also been reported in other haematological neoplasms, such as 
myelodysplasia (MDS)16,17. Over half the somatic DNMT3A mutations target a single residue, 
Arg882, with the remainder being nonsynonymous and truncating mutations scattered 
through the gene 3,15. The somatic mutational spectra thus differs from the de novo 
mutations we identified in overgrowth cases; we did not detect any Arg882 mutations and 
only two of the mutations we report, Arg749Cys and Pro904Leu, are also in the 167 
confirmed somatic DNMT3A mutations in haematological malignancies in the COSMIC 
database (Supplementary Table 2).  
Protein structure modelling suggests the Arg882 somatic mutations affect DNA binding and 
functional analyses demonstrate mutations at this residue result in reduced 
methyltransferase activity, possibly through a dominant-negative mechanism4,15,18. To 
explore the potential impact of the DNMT3A overgrowth mutations we undertook protein 
structure modelling which revealed the residues targeted by nonsynonymous mutations in 
the MTase domain appear to be located at the interaction interface with the ADD domain, 
whereas those in the ADD domain are close to the histone H3 binding region (Figure 3). The 
Arg767 residue in the MTase domain that is mutated by a frameshifting insertion is situated 
at the interface between DNMT3A and DNMT3L. Thus, whilst none of the overgrowth 
mutations appear likely to affect DNA binding, their position and the role of the ADD domain 
in the recognition of unmethylated lysine 4 of histone H3 suggest they may interfere with 
domain-domain interactions and histone binding, thereby disrupting de novo methylation19. 
Taken together these data are intriguing as they show both clear differences and some 
overlap between the DNMT3A mutational spectra in malignancies and overgrowth. The 
mechanism of pathogenesis in DNMT3A overgrowth syndrome is currently unclear though a 
simple haploinsufficiency model appears unlikely given the small proportion of truncating 
mutations. Of note, parents of Dnmt3a knockout mice are grossly phenotypically normal, 
though it is unclear whether this is because loss of function of one Dnmt3a copy is not 
associated with overgrowth, or because the overgrowth phenotype is too subtle to detect in 
mice9. Further functional and mutational analyses will be of interest, to extend and illuminate 
these observations. Long-term follow-up of individuals with DNMT3A overgrowth syndrome, 
with particular focus on cancer incidence, will also be of interest. To date, none of the 
probands have developed malignancies, though the oldest is only 29 years of age. 
Haematological malignancies with somatic DNMT3A mutations typically occur in middle-
aged individuals3,4, and it is thus possible that an increased cancer risk only manifests at 
older ages.  
DNMT3A joins an emerging family of genes with dual roles in the pathogenesis of syndromic 
overgrowth and myeloid neoplasms. Other similar genes include EZH2 and NSD15. The 
overgrowth phenotypes associated with EZH2 and NSD1 constitutional mutations, which are 
called Weaver and Sotos syndrome respectively, are similar to each other and to DNMT3A 
overgrowth syndrome5,8,20. Somatic EZH2 mutations, both activating and inactivating, occur 
in AML and poor prognosis myeloproliferative neoplasms and myelodysplastic 
syndromes15,21.  Somatic NSD1 point mutations are rare4 but the NUP90-NSD1 fusion 
protein, generated through the recurrent translocation, t(5;11)(q35.3;p15.5) is present in 
approximately 5% of childhood acute myeloid leukaemia22. Both EZH2 and NSD1 are 
histone methyltransferases that play key roles in regulation of transcription through histone 
modification and chromatin modelling. EZH2 catalyses the trimethylation of lysine residue 27 
in histone H3 (H3K27me3) and is associated with transcriptional repression, whereas NSD1 
preferentially catalyses methylation of lysine residue 36 of histone H3 (H3K36) and is 
primarily associated with transcriptional activation23,24. Of note, another gene involved in 
chromatin modification that is often mutated in AML and MDS, ASXL1, is also associated 
with a growth disorder15,25. Constitutional de novo truncating ASXL1 mutations cause 
Bohring-Opitz syndrome, a rare disorder characterised by severe undergrowth, severe 
intellectual disability, a characteristic facial appearance and flexion deformities25. This 
suggests other epigenetic regulatory genes somatically mutated in haematological 
malignancies, such as TET2, IDH1 and IDH2 would be worth evaluating in developmental 
growth disorders15.    
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Figure Legends 
Figure 1. DNMT3A structure and mutations. Schematic representation of the protein 
structure of DNMT3A with (a) de novo mutations identified in overgrowth cases placed 
above the protein and (b) nonsynonymous variants identified in controls placed below the 
protein.  
 
Figure 2. Characteristic facial appearance DNMT3A overgrowth syndrome. 
The mutation, growth parameters and other clinical features are given in Table 1 under the 
appropriate COG ID: (a) COG1288; (b) COG1670; (c) COG0422; (d) COG1695; (e) 
COG1688; (f) COG0109; (g) COG0553; (h) COG1512. Specific consent to publish facial 
photographs was obtained for all individuals.  
 
Figure 3. Mutations mapped onto a structural model of the DNMT3A-DNMT3L complex. 
Two orientations of a model of the DNMT3A monomer generated by superposition of 
structures of the DNMT3A ADD domain (cyan), the DNMT3A MTase domain (light orange) 
and full-length DNMTL (green) show mutations in the MTase domain in purple and mutations 
in the ADD domain in pink. The histone peptide bound to the ADD domain is shown in 
orange and the position of the DNA is inferred by superposition of the structurally 
homologous bacterial cytosine methyltransferase HhaI-DNA complex. The model shows that 
the mutations in the MTase domain appear to be located at the interaction interface with its 
ADD domain and at the interface with DNMT3L. Mutations in the ADD domain are close to 
the histone-binding region. 
Table 1 DNMT3A mutations and associated clinical features 
 
 
*This is the age at which growth parameters were measured.  
Abbreviations: sd, standard deviations with reference to the mean (UK90 growth data); na, not available
  Height OFC Age* Intellectual  
Case ID Mutation Protein alteration /sd /sd /yrs disability Other clinical features  
COG0274 c.889_891delTGG p.Trp297del 2.6 2.2 3.0 moderate Seizures 
COG1770 c.929T>A p.Trp297del 2.9 3.7 9.0 moderate Ventriculomegaly, umbilical hernia, scoliosis 
COG1670 c.934_937dupTCTT p.Trp297del 3.2 2.8 20.5 moderate 
COG0141 c.1594G>A p.Trp297del 2.3  na 5.9 moderate   
COG0422 c.1643T>A p.Met548Lys 1.9 1.2 4.1 moderate Atrio-septal defect 
COG1288 c.1645T>C p.Cys549Arg 1.8 3.8 11.3 moderate Atrio-septal defect, sagittal craniosynostosis 
COG0553 c.1943T>C p.Leu648Pro 3.4 5.1 19.0 mild Mild hemihypertrophy, umbilical hernia 
COG1688 c.2099C>T p.Pro700Leu 2.8 2.1 13.0 moderate Scoliosis 
COG1695 c.2245C>T p.Arg749Cys 4.0 3.8 12.0 moderate Vesico-ureteric reflux, patella subluxation 
COG1512 c.2297dupA p.Arg767fs 3.8 1.6 8.2 moderate   
COG1771 c.2512A>G p.Asn838Asp 4.2 1.7 13.4 mild Testicular atrophy, seizures, scoliosis 
COG0109 c.2705T>C p.Phe902Ser 2.7 1.3 9.8 moderate Mitral and tricuspid regurgitation, kyphoscoliosis 
COG1677 c.2711C>T p.Pro904Leu 3.7 1.2 11.0 moderate   
METHODS 
Patient samples 
Individuals with overgrowth were recruited through the Childhood Overgrowth Study. The 
research has approval from the London Multicentre Ethics Committee (Reference: 
MREC/01/2/44) and informed consent was obtained from all participants and/or families. 
DNA was extracted from peripheral blood and was available from all probands and their 
parents. Detailed phenotypic information, through a standardised questionnaire and 
photographs was also obtained. Specific consent to publish facial photographs was 
obtained. A full list of collaborators is given in the Supplementary Note.  
 
Control samples 
We used lymphocyte DNA from 1000 population-based controls obtained from the 1958 
Birth Cohort Collection, a continuing follow-up of persons born in the United Kingdom in one 
week in 1958. Biomedical assessment was undertaken during 2002-2004 at which blood 
samples and informed consent were obtained for creation of a genetic resource. 
http://www.cls.ioe.ac.uk/ 
 
Exome sequencing 
We prepared DNA libraries from 1.5 µg blood-derived genomic DNA using the Paired-End 
DNA Sample Preparation Kit (Ilumina). DNA was fragmented using Covaris technology and 
the libraries were prepared without gel size selection. We performed target enrichment using 
the TruSeq Exome Enrichment Kit (Illumina) targeting 62 Mb of the human genome. The 
captured DNA libraries were PCR amplified using the supplied paired-end PCR primers. 
Sequencing was performed with an Illumina HiSeq2000 generating 2 x 101 bp reads. 
 
Exome variant calling and de novo mutation detection 
We mapped sequencing reads to the human reference genome (hg19) using Stampy 
version 1.0.1426. Duplicate reads were flagged using Picard version 1.60 
(http://picard.sourceforge.net). Median coverage of the target at 15X was 91% across the 
1030 individuals (1000 controls and 30 individuals from the 10 overgrowth trios), with a 
median of 47,215,315 reads mapping to the target. We used Platypus version 0.1.5 to 
perform variant calling27 and SAVANT, a custom strand-aware variant annotation tool written 
in Python which follows HGVS nomenclature and ensures consistent annotation of indels, 
shifting them to their most 3’ position in the transcript. This script is available on request. We 
used an R script to identify variants present in cases but not either parent which is available 
on request.  
 
DNMT3A mutation analysis 
We performed Sanger sequencing of PCR products from genomic DNA to confirm the 
mutations identified by exome sequencing, and to mutationally analyse the gene in the 
overgrowth series. We designed PCR primers to amplify the 22 coding exons and intron-
exon boundaries of DNMT3A in 4 multiplex PCR reactions (Supplementary Table 1). The 
PCR was carried out using a Qiagen Multiplex PCR kit according to the manufacturer’s 
instructions. Products were sequenced with the original PCR primers or internal sequencing 
primers (exons 3, 6, 8, 10, 14 and 22) using the BigDye Terminator Cycle Sequencing Kit 
and an ABI 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA,USA). Sequences 
were analyzed using Mutation Surveyor software v3.97 (SoftGenetics, State College, PA, 
USA), and verified by manual inspection. All mutations were confirmed by bidirectional 
sequencing of a second, independently amplified PCR product. 
 
Statistical Analysis 
The frequency of mutations in cases and controls was compared using a two-sided Fisher’s 
exact test. 
 
 
Protein structure modelling of mutations 
The model of the DNMT3A-DNMT3L complex was created using the crystal structures of the 
DNMT3A ADD domain (PDB 3A1B), the DNMT3A MTase domain (PDB 2QRV) and full 
length DNMT3L (PDB 2PVC). The bound DNA was positioned by superposing the crystal 
structure of bacterial cytosine methyltransferase HhaI in complex with DNA (PDB 1MHT). 
First, the structure of partial DNMT3L in complex with DNMT3A was superposed onto the 
structure of full-length DNMT3L to reveal the interactions of the full length DNMT3L with 
DNMT3A. Subsequently, the ADD domain of DNMT3A was positioned by superposing it 
onto the homologous region of the second molecule of full-length DNMT3L. Finally, the DNA 
was positioned by superposing the crystal structure of bacterial cytosine methyltransferase 
HhaI in complex with DNA onto the MTase domain of DNMT3A, placing the DNA at the 
SAM/DNA binding region. The image was depicted using PyMOL visualization software (The 
PyMOL Molecular Graphics System, Version 1.6.0.0 Schrödinger, LLC.). 
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